LAIYANG,
China,
Jan. 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo
Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"),
a pharmaceutical company with its principal operations in
China, today
announced that its Osteomyelitis treatment tablets (
Kang Gu Sui Yan Pian) has
been included in the 2009 Edition of the National Basic Medical Insurance,
Industrial Injury Insurance and Maternity Insurance Medicine Directory ("the
Directory").
Jiangbo is the exclusive manufacturer of Osteomyelitis treatment tablets
in
China. This product is used to treat bone and bone marrow inflammations.
It's a 100% herb-based traditional Chinese medicine. Most osteomyelitis
patients currently use chemical drugs such as antibiotics for treatment which
may develop drug resistance if the chemical drugs are taken over a long period
of time. Chronic patients are also likely to need surgery which is a less
preferable treatment for patients in
China. Jiangbo's Osteomyelitis treatment
tablets offer an alternative mild treatment and were clinically tested to be
effective in treating long term osteomyelitis problems.
The Company has four other products which have been included in the
Directory. They are Radix Isatidis Granules, Motherwort Herb Electuary (
Yi Mu
Cao Gao), Ciprofloxacin Hydrochloride tablets and Paracetamol tablets.
Currently, the Company is producing limited quantities of these four products.
"The inclusion of Osteomyelitis treatment tablets in the 2009 Edition
Directory is an important accomplishment for our Company," said Mr. Wubo Cao,
the Company's Chief Executive Officer. "As its exclusive manufacture, we
expect the inclusion of Osteomyelitis treatment tablets in the Directory to
drive meaningful sales volume growth in future."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development,
production, marketing and sales of pharmaceutical products in
China. The
Company's operations are located in
Eastern China in an Economic Development
Zone in Laiyang City,
Shandong Province. Jiangbo produces both western and
Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and
electuary (sticky syrup) form. For additional information, please visit the
Company's website ( http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company's actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from anticipated or predicted results, and reported results should
not be considered as an indication of future performance. The potential risks
and uncertainties include, among others, the Company's ability to obtain raw
materials needed in manufacturing, anticipated sales volume growth of the
medicines, the continuing employment of key employees, the failure risks
inherent in testing any new drug, the possibility that regulatory approvals
may be delayed or become unavailable, patent or licensing concerns that may
include litigation, direct competition from other manufacturers and product
obsolescence. More information about the potential factors that could affect
the Company's business and financial results is included in the Company's
filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.
Careers
